Artificial sweeteners--enhancing glycosylation to treat muscular dystrophies.
Rando
Thomas A
TA
Department of Neurology and Neurological Sciences, Stanford University, and the Neurology Service, Veterans Affairs Palo Alto Health Care Systems, Palo Alto, California, USA.
D000818:Animals; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D004195:Disease Models, Animal; D049030:Dystroglycans; D016189:Dystrophin / Q000172:deficiency / Q000378:metabolism*; D015316:Genetic Therapy; D006031:Glycosylation; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008565:Membrane Proteins / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009136:Muscular Dystrophies / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D017350:N-Acetylgalactosaminyltransferases / Q000378:metabolism; D017351:N-Acetylglucosaminyltransferases / Q000172:deficiency / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000172:deficiency / Q000378:metabolism*; D013602:T-Lymphocytes, Cytotoxic; D015854:Up-Regulation; D049411:Utrophin
D003598:Cytoskeletal Proteins; C483081:DAG1 protein, human; D016189:Dystrophin; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D009363:Neoplasm Proteins; C483600:Utrn protein, mouse; D049411:Utrophin; D049030:Dystroglycans; C117674:LARGE1 protein, human; D017350:N-Acetylgalactosaminyltransferases; D017351:N-Acetylglucosaminyltransferases